Nodexus is democratizing access to live single cells for applications including gene editing, drug development, and more.
Nodexus is a Venture- and SBIR-backed biotech startup commercializing the NX One platform to address widespread unmet needs for accessible live single cell isolation in industrial/biopharma, clinical research, and academic sectors. The NX One platform consists of a low-infrastructure, low-cost hardware system and single-use disposable microfluidic cartridges tailored toward live single-cell workflows involving gene editing (e.g. CRISPR engineering), cell line/antibody development, and tumor heterogeneity studies.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jul 11, 2019 | Grant | — | 1 | National Science Foundation | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
National Science Foundation | Yes | Grant |